logo
Plus   Neg
Share
Email

Eurofins U.S. Clinical Diagnostics Unveils Lower Cost COVID-19 PCR Test

Eurofins U.S. Clinical Diagnostics, affiliated to Eurofins Scientific (ERFSF.PK, EUFI.PA), announced Wednesday the launch of lower cost highly accurate COVID-19 PCR test.

The test will be offered through its network of U.S. laboratories, including Viracor Eurofins beginning mid-August.

The company said its pooled PCR test to detect SARS-CoV-2 can significantly reduce the price per PCR test for clients.

Pooling can be used to continuously and cost-effectively monitor prescreened, low-risk groups that show a low prevalence of COVID-19 infection. It can also be used as part of surveillance testing for positive individuals in quarantine.

In pooled testing, Eurofins will pool five specimens and then test a single PCR assay while retaining the original, individual samples. Results are typically provided within 24-48 hours.

If SARS-CoV-2 is detected in the pool, individual PCR tests will be performed to definitively identify the individual sample that were positive. If there is no virus detected in the pool, no further testing is required.

According to the company, weekly or bi-weekly pooling in combination with other Eurofins' SARS-CoV-2 antibody, surface, wastewater, air and used mask assays, can help organisations reduce the risk of the current pandemic for significantly less than using regular PCR tests.

Eurofins U.S. Clinical Diagnostics division submitted its pooling assay to the FDA for an Emergency Use Authorization on July 24. Eurofins started PCR pooling tests in Germany in early July 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
RELATED NEWS
Follow RTT